

FOI – 2382

13th June 2024

## **FREEDOM OF INFORMATION ACT 2000 – INFORMATION REQUEST**

---

**Please answer the questions with regards to NHS patients, i.e., excluding patients that received treatment as part of clinical trials or private healthcare.**

**1. Do you treat patients with acute myeloid leukaemia (AML) in your Trust?**

**Response:**

Yes, some in Southern Trust and some treated via Belfast City Hospital

***If yes, please proceed to Question 3, if no, please answer Question 2***

**2. Where do patients diagnosed with AML in your Trust receive treatment?**

**Response:**

Haematology Ward & Mandeville Unit, Craigavon Area Hospital

**3. Please complete the table below with how many newly diagnosed patients with AML have started first-line treatment with each of the following therapies during the 6-month period October 2023 to March 2024?**

- Azacitidine monotherapy
- Low dose cytarabine (LoDAC) monotherapy
- Venetoclax + azacitidine
- Venetoclax + LoDAC
- Ivosidenib
- Intensive chemotherapy-based regimen
  - Examples include: cytarabine and daunorubicin, idarubicin, fludarabine, mitoxantrone, etoposide (VP-16), 6-thioguanine (6-TG), methotrexate (MTX) or 6-mercaptopurine (6-MP), gemtuzumab ozogamicin with daunorubicin cytarabine, or FLAG-Ida (fludarabine, cytarabine, granulocyte-colony stimulating factor and idarubicin)
- Best supportive care
- Other

- Do not include prophylactic therapies such as GCSF, anti-fungals, antihistamines, anti-nauseants

**Note: this should only include patients with AML who have started first-line treatment during the 6-month window**

**Response:**

Treatment option	Number of newly diagnosed patients with AML starting first line treatment during the 6-month period October 2023 to March 2024
Azacitidine monotherapy	0
(LoDAC) monotherapy	0
Venetoclax + azacitidine	1
Venetoclax + LoDAC	0
Ivosidenib	0
Intensive chemotherapy-based regimen	0 (as listed above)
Best supportive care	Pharmacy Department unable to quantify
Other	Pharmacy Department unable to quantify

**Email:** [foi.team@southerntrust.hscni.net](mailto:foi.team@southerntrust.hscni.net)